Observing the effects of intra-arterial therapies for liver cancer
Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study
This study is trying to find the best ways to help people with liver cancer get better results from a treatment called intra-arterial therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06774690 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify the optimal conditions for positive outcomes in patients receiving intra-arterial therapy (IAT) for primary liver cancers, specifically Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Researchers will collect and analyze both retrospective and prospective data from participants at the IRCCS Azienda Ospedaliera Universitaria in Bologna. The study will evaluate clinical and radiological traits, including imaging assessments, to understand treatment responses and potential complications. The study expects to enroll approximately 3,300 participants over a five-year period.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 diagnosed with HCC or iCCA who are indicated for intra-arterial therapies.
Not a fit: Patients with metastasis outside the liver or those experiencing liver failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies for liver cancer, leading to improved patient outcomes.
How similar studies have performed: While similar approaches have been explored, this study focuses on a comprehensive observational analysis, making it a novel contribution to the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of Hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA) and clinical indication to receive or have already received one of the following treatments: * Trans-arterial embolization (TAE), * Transarterial chemoembolization (TACE), * Transarterial radioembolization (TARE) * Drug-eluting beads chemoembolization (DEB-TACE) * Age over 18 * To give informed consent Exclusion Criteria: * shunt of gastro intestinal arteries that cannot be embolized * metastasis spread outside of the liver * liver failure
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Cristina Mosconi, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Cristina Mosconi, MD
- Email: cristina.mosconi@aosp.bo.it
- Phone: 0039 3498496325
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.